Post-market Follow up Study of the 'BPK-S Integration' UC as Primary Implant in the Variants CoCr or Ceramic
Launched by PETER BREHM GMBH · Sep 21, 2017
Trial Information
Current as of May 03, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Congenital or acquired knee joint defects/deformation
- • Defects or malfunction of the knee joint
- • Arthrosis (degenerative, rheumatic)
- • Post-traumatic arthritis
- • Symptomatic knee instability
- • Reconstruction of flexibility
- • Patients with metal hypersensitivity (ceramic tibia/femur)
- Exclusion Criteria:
- • Illnesses which can be treated without using a knee joint implant.
- • Acute or chronic infections near the implantation
- • Systemic diseases and metabolic disorders
- • Serious osteoporosis
- • Serious damage to the bone structures that impedes stable implantation of the implant components
- • Diseases that impair bone growth, e.g. cancer, renal dialysis, osteopenia, etc.
- • Bone tumors in the area of the implant anchoring
- • Obesity or overweight of the patient
- • Overload of the knee implant to be expected
- • Abuse of medication, drug abuse, alcoholism or mental disease
- • Pregnancy
- • Lack of patient cooperation
- • Sensitivity to foreign matter in the implant materials
- • Patients under the age of 18
- • Patients participating in another trial
About Peter Brehm Gmbh
Peter Brehm GmbH is a renowned medical technology company specializing in the development and manufacturing of innovative orthopedic implants and surgical instruments. With a commitment to enhancing patient outcomes through advanced engineering and research, the company actively participates in clinical trials to evaluate the safety and efficacy of its products. Leveraging a robust portfolio of solutions, Peter Brehm GmbH collaborates with healthcare professionals and institutions worldwide to drive forward the field of orthopedic surgery and improve the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, Oberösterreich, Austria
Patients applied
Trial Officials
Christian E. Berger, Prof.
Principal Investigator
Sozialmedizinisches Zentrum Ost - Donauspital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials